Table 1.
Advantages |
• Favorable biodistribution and blood clearance |
• High therapeutic ratio (high target to-nontarget organ ratio) |
• Flexibility with respect to isotope and antigen target |
• Multiple effector dosing possible |
• Sequential amplification possible |
Disadvantages |
• Ab constructs may be difficult to manufacture |
• Monovalent (to tumor antigen) Ab fragment constructs may decrease tumor residence time |
• Tetravalent constructs (e.g., streptavidin) may crosslink antibody–antigens and internalize |
• Immunogenicity (e.g., streptavidin) |
• Hapten release from processed Ab may poison tumor-associated conjugate |
• Perceived as complex with respect to dosing and timing |
• Rapidly internalized antigens are nontargetable |
Ab, antibody.